Rezpegaldesleukin, a novel regulatory T cell stimulator, demonstrated lasting and deepening treatment effects after one year in alopecia areata and atopic dermatitis patients. In alopecia areata, 75% of patients maintained significant hair regrowth four months off treatment, with continued improvement up to six months off treatment. In atopic dermatitis, monthly and quarterly dosing sustained disease control and increased skin clearance rates over 52 weeks. These promising Phase 2b results support ongoing Phase 3 trials, including a new study for treatment-experienced atopic dermatitis patients and a planned alopecia areata trial starting in early 2027.
Rezpegaldesleukin's new data on long-term treatment durability in alopecia areata and atopic dermatitis provides context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 01, 2026 17:52 WIB: out of 100 priced US health-sector stocks, 42 rose and 46 fell today. Notable movers include CTXR at USD 0.56 with a 1-day change of +5.08% and a typical hold time of 16 days, INO at USD 1.25 up 2.46% with a 42-day hold, and MRNA at USD 188.00 down 2.37% with a 59-day hold. Pluang order activity shows CTXR with 66% sell and 34% buy, INO with 55% sell and 45% buy, and MRNA with 79% sell and 21% buy.
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
Oklo is developing advanced fast-fission reactors to power future data centers and industrial hubs, aiming to lead in carbon-free energy. Piper Sandler reaffirmed an "Overweight" rating on the stock, reflecting confidence in Oklo's growth prospects. ...
Nike is set to release its quarterly earnings on October 1, 2026, with analysts forecasting an EPS of $0.44 and revenue of $11.32 billion, both down from last year. The company's stock has fallen 80% this year, hitting 13-year lows, reflecting a chal...
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
